$ABP News
Last published 10mo ago
- 10mo agoABPAbpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP), a clinical-stage biotechnology company developing next-generation antibody therapeutics for solid tumors, today announced that its
- 11mo agoABPAbpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive CancersGlobeNewswireIND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents Abpro's first IND
- 11mo agoABPAbpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic ObjectivesGlobeNewswireBURLINGTON, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro" or the "Company"), a biotechnology company advancing next-generation antibody therapies, today announced that it has
- 1y agoABPAbpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell EngagerGlobeNewswireCT-P72/ABP-102 poster selected as one of the Top 150 abstracts out of more than 1,300 submissions at SITC 2025 CT-P72/ABP-102 demonstrates potent and selective anti-tumor activity in HER2-high models, including
- 1y agoABPAbpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025GlobeNewswireAchieved ~60% reduction in operating costs through a focused cost optimization plan DiversImmune® platform positioned to unlock additional pipeline value Reverse stock split supports Nasdaq compliance and
- 1y agoABPCPIXXFORSitryx appoints Adam Mostafa as Chief Financial OfficerGlobeNewswireSitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8
- 1y agoABPAbpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell EngagerGlobeNewswireData suggest potential for superior tumor selectivity, potent efficacy, and improved safety profileAbpro and Celltrion have a strategic partnership for worldwide development and commercialization of
- 1y agoABPAbpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025GlobeNewswireWOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening
- 1y agoABPAbpro Statement on the Departure of Former CEO Ian ChanGlobeNewswireWOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening
- 1y agoABPAbpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell RingingGlobeNewswireBusiness combination closed November 13, 2024Raised $10 million of gross proceeds in connection with the business combinationAgreements are in place with Yorkville for up to a $50 million standby equity purchase